Interventional Glaucoma

Here is one question to help clinicians decide: ‘What is the anatomy giving me?’

Exploring broad utility of netarsudil for ROCK inhibition across spectrum of glaucoma

Research to understand underlying mechanisms may lead to clues for targeted therapy

Ophthalmology Times’ Editorial Advisory Board members share their thoughts on what to watch in year ahead

Ophthalmology benefiting from active programs for innovative product development in 2018 and onward

Orbital and adnexal anatomy and pathology can affect IOP and its measurement as well as planning of glaucoma surgery, and these structures can be affected by medical and surgical treatment of glaucoma

Optical coherence tomography angiography is finding new uses in glaucoma, as it can depict loss of blood vessels around the optic nerve and distinguish vascular layers.

Here's how your practice can utilize Facebook to reach out and spread the word about how you can help people with glaucoma.

The piezo-print microdosing delivers drugs in less than 80 milliseconds, beating the eye’s 100-millisecond reflex.

As more microinvasive glaucoma surgery (MIGS) procedures become available, surgeons are faced with decisions on adoption of new techniques.

In a small study, a combination over-the-counter supplement with antioxidant and mitoprotective properties significantly reversed mitochondrial dysfunction.

Results from MERCURY-1, a 12-month phase III pivotal trial, show that once daily treatment with fixed-dose combination netarsudil 0.02%/latanoprost 0.005% (Aerie Pharmaceuticals) is safe and provided significantly greater IOP-lowering than either of its components throughout follow-up.

Know the patient’s family history of glaucoma, and conduct a comprehensive exam before LASIK procedure. It is crucial to monitor the patient after surgery; watch for interfact cysts, loose flaps, and pressure-induced interlamellar stromal keratitis.

Jonathan S. Myers, MD, reports that intraocular drug delivery systems could help solve the problem of poor adherence in patients taking glaucoma medications. Implanted in the eye, the systems would allow for glaucoma drugs to gradually dissolve or elute medication.

Compared with SLT, PSLT appears to offer some advantages, such as a shorter duration of treatment and more comfort for patients.

Steven Vold, MD, reports that toric IOLs provide an accurate, safe, and convenient way to correct astigmatism and uncorrected distance vision for glaucoma patients, while patients wanting presbyopic correction have IOL options to fit a range of visual needs.